DOCSLIB.ORG

Methadone Maintenance Program: Clinical Practice Guideline

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Methadone Maintenance Program: Clinical Practice Guideline College of Physicians and Surgeons of Britsh Columbia Methadone Maintenance Program: Clinical Practce Guideline February 2014 Revised July 2014 | Updated September 2015 Methadone Maintenance Program: Clinical Practice Guideline CONTENTS Preface .................................................................................................... 1 Introduction ............................................................................................ 2 1. The History of Methadone .................................................................................................................. 2 2. Authorization to Prescribe Methadone .............................................................................................. 2 2.1 Full Authorization ...................................................................................................................... 3 2.2 Temporary Authorization .......................................................................................................... 4 2.3 Hospitalist Authorization ........................................................................................................... 4 3. Pharmacology of Methadone ............................................................................................................. 4 3.1 Absorption ................................................................................................................................. 5 3.2 Duration of Action/Metabolism ................................................................................................ 5 3.3 Tolerance ................................................................................................................................... 5 Admission to the Methadone Maintenance Program ............................. 6 1. Criteria for Admission to the Methadone Maintenance Program ...................................................... 6 2. DSM-IV-TR Diagnostic Definition of Opioid Use Disorder ................................................................... 7 3. Treatment Considerations .................................................................................................................. 8 3.1 Detoxification ............................................................................................................................ 8 3.2 Outpatient and Day Treatment Programs ................................................................................. 8 3.3 Residential and Support Recovery Programs ............................................................................ 8 3.4 Alternative Pharmacotherapies ................................................................................................ 8 3.5 Mutual Support Groups ............................................................................................................. 9 3.6 Mental Health Services .............................................................................................................. 9 Assessment for Initiation ...................................................................... 10 1. Assessment Checklist ........................................................................................................................ 10 2. Treatment Goals and Plans ............................................................................................................... 11 3. Problematic Alcohol Use ................................................................................................................... 11 4. Process (Behavioural) Addictions ...................................................................................................... 12 College of Physicians and Surgeons of British Columbia i September 2015 Methadone Maintenance Program: Clinical Practice Guideline Contents Maintenance and Monitoring ............................................................... 14 1. Methadone Dosing ............................................................................................................................ 14 1.1 Initiation (Induction)................................................................................................................ 14 1.2 Titration ................................................................................................................................... 15 1.3 Stabilization ............................................................................................................................. 16 1.4 Split Doses ............................................................................................................................... 16 1.5 Missed Doses ........................................................................................................................... 17 1.6 Dosing Precautions .................................................................................................................. 18 1.6.1 Side Effects of Methadone ......................................................................................... 18 1.6.2 Toxicity ....................................................................................................................... 19 1.6.3 Fatal Overdoses .......................................................................................................... 19 2. Urine Drug Testing (UDT) .................................................................................................................. 20 2.1 When and Why to Order UDT ................................................................................................. 20 2.2 Method of Collection ............................................................................................................... 20 2.3 Urine Toxicology ...................................................................................................................... 20 3. Carry Privileges .................................................................................................................................. 22 3.1 Criteria for Initiating Methadone Carries ................................................................................ 22 3.1.1 Biopsychosocial Stability ............................................................................................ 22 3.1.2 Safe Methadone Storage ............................................................................................ 22 3.2 Carry Schedule ......................................................................................................................... 23 3.3 Exceptions to Carry Guidelines ................................................................................................ 23 3.4 Prescriptions for Carries .......................................................................................................... 23 3.5 Reassessment of Carry Privileges ............................................................................................ 23 4. Counselling ........................................................................................................................................ 24 4.1 The Methadone Prescriber’s Role ........................................................................................... 24 4.2 Brief Interventions ................................................................................................................... 25 4.3 Transtheoretical Model of Change .......................................................................................... 26 4.4 Community Substance Use Services........................................................................................ 26 5. Documentation of Benefits ............................................................................................................... 27 5.1 Categories of Benefits ............................................................................................................. 27 6. Prescriptions for Methadone Maintenance ...................................................................................... 28 College of Physicians and Surgeons of British Columbia ii September 2015 Methadone Maintenance Program: Clinical Practice Guideline Contents Discontinuation of Methadone Maintenance Treatment ..................... 30 1. Discontinuation in Stable Patients: Treatment Goals Achieved ....................................................... 30 2. Discontinuation in Unstable Patients: Treatment Goals Not Achieved ............................................ 31 3. Involuntary Dismissal ........................................................................................................................ 31 4. Transfer of Care ................................................................................................................................. 31 Advice to Physicians Downsizing or Leaving Their Methadone Maintenance Practices .......................................................................... 33 Special Populations ............................................................................... 34 1. Introduction ...................................................................................................................................... 34 2. Adolescent Patients........................................................................................................................... 34 3. Women of Child-Bearing Potential ................................................................................................... 35 4. Pregnant Women .............................................................................................................................
Load more

Recommended publications
  • Impact of Recreational and Medical Marijuana Use During Pregnancy and Lactation on the Newborn
    If it’s Legal it Can’t be all Bad… can it? Impact of Recreational and Medical Marijuana use during Pregnancy and Lactation on the Newborn Moni Snell MSN RN NNP-BC Neonatal Nurse Practitioner NICU Regina Qu’Appelle Health Region Objectives Understand the current use, risks and differences between medical (CBD) and recreational (THC) marijuana Discuss evidence based education for women and current management strategies for caring for newborns exposed to THC through pregnancy and breastfeeding Discuss the impact of increased newborn exposure to recreational and medical marijuana with it’s legalization Marijuana… common term for Recreational Cannabis in the form of dried leaves, stems or seeds Anticipated legalization in Canada July 2018 Currently legal in 29 states in the US Recreational use and self –medication with cannabis is very common • Cannabis: pot, grass, reefer, weed, herb, Mary Jane, or MJ Peak use is in the 20’s and 30’s : women’s • Contains over 700 chemicals, about 70 of reproductive years which are cannabinoids • Hash and hash oil also come from the cannabis plant Cannabis Ingredients Tetrahydrocannabinol (THC) is the chemical that makes people high Cannabidiol (CBD) is known for its medicinal qualities for pain, inflammation, and anxiety o CBD does not make you feel as high Different types of cannabis and effects depend on the amount of THC or CBD, other chemicals and their interactions THC content is known to have increased over the past several decades Oils have higher percentage of THC and THC in edible cannabis products can vary widely and can be potent THC content/potency of THC confiscated by DEA in US has been steadily increasing Consequences could be worse than in the past, especially among new users or in young people with developing brains ElSohly et al, (2016) Changes in cannabis potency over the last 2 decades (1995-2014): Analysis of current data in the United States.
    [Show full text]
  • The Motherisk Alcohol and Substance Use Helpline: 10 Years of Experience and Counting
    THE MOTHERISK ALCOHOL AND SUBSTANCE USE HELPLINE: 10 YEARS OF EXPERIENCE AND COUNTING Eunji Kim, Moumita Sarkar, Yvette Navioz, Gideon Koren, Adrienne Einarson The Alcohol and Substance use Helpline; The Motherisk Program, The Hospital for Sick Children, Toronto, Canada ABSTRACT The Motherisk Alcohol and Substance Use Helpline at The Hospital for Sick Children in Toronto, Canada, is a unique telephone service providing evidence-based information on the negative effects associated with alcohol and substance use in pregnancy and lactation. We describe the characteristics of the service, the demographics of the callers, and the inquiries made during its first ten years of service. Since its inception in November 1998 until November 2008, almost 20,000 calls had been received with 60% of calls initiated by pregnant and breastfeeding women, the remainder from various health care providers. Most women exposed to alcohol and substances were of Caucasian descent (80%), employed (65%), and married (46%) with some level of post-secondary education (52%). The demographics of the callers deviate from the well-documented cohort of women at risk of engaging in alcohol and substance use in pregnancy and lactation, confirming that a selective group of women is more likely to use the services offered by the Motherisk program. Thus, further efforts are required to reach out to the subgroup of women at high risk of continuing their harmful behaviors during pregnancy and lactation. Key Words: Alcohol; pregnancy; fetal alcohol spectrum disorder; substance use; childbearing age lcohol consumption is a wide spread following gestational exposures.6-9 Fetal Alcohol social behavior with reported use by 77% Spectrum Disorder (FASD) describes the physical Aof Canadian women 15 years and older.1 and neurological abnormalities resulting from Other substances such as tobacco and illicit drugs prenatal exposure to alcohol with symptoms are also used recreationally by many women of ranging from neurobehavioral and neurocognitive childbearing age.
    [Show full text]
  • Licit and Illicit Drug Use During Pregnancy: Maternal, Neonatal and Early Childhood Consequences
    SUBSTANCE ABUSE IN CANADA 2013 Licit and Illicit Drug Use during Pregnancy: Maternal, Neonatal and Early Childhood Consequences By Loretta Finnegan With A Call to Action by Franco Vaccarino and Colleen Dell This document was published by the Canadian Centre on Substance Abuse (CCSA). CCSA activities and products are made possible through a financial contribution from Health Canada. The views of CCSA do not necessarily represent the views of the Government of Canada. The subjects in the photographs used throughout this publication are models who have no relation to the content. The vignettes are fictional and do not depict any actual person. Suggested citation: Finnegan, L. (2013). Substance abuse in Canada: Licit and illicit drug use during pregnancy: Maternal, neonatal and early childhood consequences. Ottawa, ON: Canadian Centre on Substance Abuse. © Canadian Centre on Substance Abuse 2013. CCSA, 75 Albert St., Suite 500 Ottawa, ON K1P 5E7 Tel.: 613-235-4048 Email: [email protected] This document can also be downloaded as a PDF at www.ccsa.ca. Ce document est également disponible en français sous le titre : Toxicomanie au Canada 2013 : Consommation de drogues licites et illicites pendant la grossesse : Répercussions sur la santé maternelle, néonatale et infantile ISBN 978-1-77178-041-4 Licit and Illicit Drug Use during Pregnancy: Maternal, Neonatal and Early Childhood Consequences Prepared for the Canadian Centre on Substance Abuse Loretta P. Finnegan, M.D., LLD, (Hon.), ScD (Hon.); President, Finnegan Consulting, LLC; Professor of Pediatrics, Psychiatry and Human Behavior, Thomas Jefferson University (Retired); Founder and Former Director of Family Center, Comprehensive Services for Pregnant Drug Dependent Women, Philadelphia, PA; Former Medical Advisor to the Director, Office of Research on Women’s Health, National Institutes of Health, U.S.
    [Show full text]
  • Pharmacological Treatment for Pregnant Women Who Smoke Cigarettes
    TOBACCO INDUCED DISEASES Vol. 1, No. 3: 165-174 (2003) © PTID Society Pharmacological Treatment for Pregnant Women who Smoke Cigarettes Chan BC, Koren G The Motherisk Program, Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada ABSTRACT: Smoking has been associated with several concerns in pregnancy including miscarriage, preterm delivery and stillbirth. Unfortunately, approximately 12% of the preg- nant population continue to smoke cigarettes, suggesting a need for additional therapy be- yond behavioural change. This paper reviews the literature on the use of nicotine replace- ment therapy and bupropion (Zyban®) in the pregnant human population, the pharmaco- kinetics of nicotine in the pregnant woman, and current guidelines for smoking cessation for pregnant patients. There are currently four studies that have investigated the use of nicotine patch, three for nicotine gum, and registry and preliminary reports for bupropion. These studies did not show any adverse pregnancy outcomes with the use of pharmacological aid for smoking cessation. All the nicotine replacement therapy studies, with the exception of one randomized-controlled nicotine patch trial had small sample sizes and looked at short- term use of drug in the third trimester. Two studies have examined the pharmacokinetics of nicotine in the pregnant woman. The results from these studies reveal greater nicotine me- tabolism in pregnant individuals who continue to smoke during pregnancy. Current guide- lines from several organizations uniformly recommend that Nicotine Replacement Therapy should be considered if non-pharmacological therapies have been unsuccessful. Bupropion is recommended in pregnancy if the benefits outweigh the risks. There is a need for further studies on the safety and effectiveness of Nicotine Replacement therapy and bupropion in pregnancy.
    [Show full text]
  • Harmful Impacts: the Reliance on Hair Testing in Child Protection Report of the Motherisk Commission the Honourable Judith C
    Harmful Impacts: The Reliance on Hair Testing in Child Protection Report of the Motherisk Commission The Honourable Judith C. Beaman Commissioner February 2018 This Report is available at Motherisk Commission (https://motheriskcommission.ca). © 2018 Ministry of the Attorney General ISBN 978-1-4868-1372-8. Print. [English]. ISBN 978-1-4868-1378-0. Print. [Cree]. ISBN 978-1-4868-1373-5. PDF. [English]. ISBN 978-1-4868-1379-7. PDF. [Cree]. ISBN 978-1-4868-1374-2. Print. [French]. ISBN 978-1-4868-1380-3. Print. [Oji-Cree]. ISBN 978-1-4868-1375-9. PDF. [French]. ISBN 978-1-4868-1381-0. PDF. [Oji-Cree]. ISBN 978-1-4868-1376-6. Print. [Mohawk]. ISBN 978-1-4868-1382-7. Print. [Ojibway]. ISBN 978-1-4868-1377-3. PDF. [Mohawk]. ISBN 978-1-4868-1383-4. PDF. [Ojibway]. |2| Harmful Impacts: The Reliance on Hair Testing in Child Protection Report of the Motherisk Commission To recognize the broad harm caused by the unreliable Motherisk hair testing, the Commission considered “affected persons” to include children, siblings, biological parents, adoptive parents, foster parents, extended families, and the bands or communities of Indigenous children. This Report is dedicated to everyone who was affected by the testing. February 26, 2018 The Honourable Yasir Naqvi Attorney General of Ontario Ministry of the Attorney General McMurtry-Scott Building 720 Bay Street, 11th Floor Toronto, ON M7A 2S9 Re: Motherisk Commission Dear Minister: With this letter, I am delivering the Report of the Motherisk Commission, Harmful Impacts: The Reliance on Hair Testing in Child Protection. Establishing the Motherisk Commission served as public acknowledgement that the unreliable hair testing by the Motherisk Drug Testing Laboratory deeply affected Ontario families.
    [Show full text]
  • Women and Psychosis: an Information Guide 1
    3mm Women and psychosis Women Psychosis refers to a loss of contact with reality, in which people have trouble distinguishing between what is real and what is not. Psychosis can be frightening, confusing and distressing. Women This guide is written for women who have had a psychotic episode, and for their families. An information guide It explains: and psychosis · what psychosis is ·what the recovery process is like, especially for women ·how psychosis affects family and friends ·how a woman with psychosis can manage her future. An This valuable guide gives essential information and support to women with psychosis and the people in their lives. information This publication may be available in other formats. guide For information about alternate formats or other CAMH publications, or to place an order, please contact Sales and Distribution: Toll-free: 1 800 661-1111 revised edition Toronto: 416 595-6059 E-mail: [email protected] Online store: http://store.camh.ca Pamela Blake, MSW, RSW April A. Collins, MSW, RSW Website: www.camh.ca Mary V. Seeman, MD Disponible en français. Revised by Mary V. Seeman, MD ISBN 978-1-77052-635-8 A Pan American Health Organization / World Health Organization Collaborating Centre 3973m / 02-2016 PM119 i Women and psychosis An information guide Pamela Blake, MSW, RSW April A. Collins, MSW, RSW Mary V. Seeman, MD Revised by Mary V. Seeman, MD A Pan American Health Organization / World Health Organization Collaborating Centre ii Library and Archives Canada Cataloguing in Publication Blake, Pamela, 1954-, author Women and psychosis : an information guide : a guide for women and their families / Pamela Blake, MSW, RSW, April A.
    [Show full text]
  • Rates of Fetal Polydrug Exposures in Methadone- Maintained Pregnancies from a High-Risk Population
    Rates of Fetal Polydrug Exposures in Methadone- Maintained Pregnancies from a High-Risk Population Kaitlyn Delano1,2, Joey Gareri1,3, Gideon Koren1,2,4* 1 Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children, Toronto, Ontario, Canada, 2 Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada, 3 Department of Pharmaceutical Sciences, University of Toronto, Toronto, Ontario, Canada, 4 Department of Physiology and Pharmacology, University of Western Ontario, London, Ontario, Canada Abstract Methadone maintenance treatment (MMT) is the standard of care during pregnancy for opioid-dependency, showing efficacy in improving prenatal care and reducing risk of relapse. By design, however, MMT is only intended to prevent withdrawal thus facilitating cognitive behavioural interventions. In order to maximize the benefits of MMT, it is essential that methadone is both properly prescribed and that additional addiction treatment is concurrently administered. This study aims to determine the effectiveness of MMT engagement in high-risk pregnant women in reducing polydrug use by objective laboratory examination of neonatal meconium. Patients and Methods: Over a 29-month period, the Motherisk Laboratory at the Hospital for Sick Children in Toronto analyzed meconium samples as per request by social services and hospitals for drugs of abuse. Results: Of the 904 meconium samples received, 273 were tested for methadone with 164 positive and 109 negative for methadone. Almost half of the methadone positive samples (46.34%) were also positive for at least one other opioid compound, which did not differ statistically from the methadone-negative control samples (46.79%; Chi square test, p=0.94). No differences were found between the methadone positive and negative groups in rates of concurrent amphetamines, cocaine, cannabis, and alcohol use indicating a similar risk of polydrug use between pregnant women taking or not taking methadone in this population.
    [Show full text]
  • Motherisk Update Marijuana Use and Breastfeeding Josephine Djulus, MD Myla Moretti, MSC Gideon Koren, MD, FRCPC
    Pratique clinique Clinical Pract ice Motherisk Update Marijuana use and breastfeeding Josephine Djulus, MD Myla Moretti, MSC Gideon Koren, MD, FRCPC ABSTRACT QUESTION One of my breastfeeding patients is using marijuana to combat chronic pain. Is it safe for her to breastfeed? ANSWER Lactating mothers should refrain from consuming cannabinoids. Advising mothers to discontinue breastfeeding if they cannot stop using cannabinoids must incorporate the known risks of formula feeding. Cannabinoid exposure through milk has not been shown to increase neonatal risk, but there are no appropriate studies of this. In every case, nursing babies should be closely monitored. RÉSUMÉ QUESTION L’une de mes patientes allaite et consomme de la marijuana pour atténuer ses douleurs chroniques. Est-ce sans danger qu’elle allaite? RÉPONSE Les mères qui allaitent devraient s’abstenir de consommer des cannabinoïdes. En conseillant aux femmes de cesser d’allaiter si elles ne peuvent pas arrêter de consommer des cannabinoïdes, il faut aussi les aviser des risques connus du recours à l’allaitement artifi ciel. Il n’a pas été démontré que l’exposition aux cannabinoïdes dans le lait maternel augmentait les risques chez les nouveau-nés mais il n’existe aucune étude adéquate sur le sujet. Dans tous les cas, les nourrissons devraient faire l’objet d’une étroite surveillance. espite abundant recreational use of canna- and reaction time, altered perception, impaired binoids by women of reproductive age, very coordination and motor performance, poor short- Dlittle is known about marijuana use and lactation. term memory, impaired attention and judgment, Th e Motherisk Program’s Alcohol and Substance panic attacks, anxiety, dizziness, and general dif- Use Helpline receives about three calls a week fi culty expressing even simple thoughts in words.
    [Show full text]
  • Risks of Cannabis on Fertility, Pregnancy, Breastfeeding And
    Risks of Cannabis on Fertility, Pregnancy, Breastfeeding and Parenting About this resource This resource is for women and men who are thinking about becoming parents, are pregnant, or who are new parents. It provides information about the effects of cannabis: v On fertility, pregnancy and breastfeeding v On children and adolescents, when their mothers used cannabis during pregnancy v On parenting Legal use of cannabis doesn’t necessarily make it safe. Using cannabis can have effects on health, learning, relationships, fertility, pregnancy and children. This resource summarizes the current knowledge about the effects of cannabis. It does not focus on any potential therapeutic medical benefits of cannabis. TABLE OF CONTENTS What is cannabis? ..................................................................................................... 1 Key effects of cannabis .............................................................................................. 2 Effects of cannabis when planning a pregnancy, when pregnant, and breastfeeding .................................................................................................. 3-4 Long term effects on children and teens .................................................................... 5 Parenting and cannabis .......................................................................................... 6-8 Who to call for information or help ........................................................................... 9 Resources .................................................................................................................
    [Show full text]
  • Neonatal Abstinence Syndrome (NAS) Clinical Guidelines
    Final: July 19, 2011 | Revised: March 30, 2012; November 25, 2016 NEONATAL ABSTINENCE SYNDROME (NAS) CLINICAL PRACTICE GUIDELINES TABLE OF CONTENTS Introduction .................................................................................................................................... 2 Table 1 – Levels of Evidence ............................................................................................... 3 Glossary of Terms ........................................................................................................................... 4 Summary of Clinical Practice Recommendations ......................................................................... 5 Clinical Practice Recommendations .............................................................................................. 7 Table 2 – NAS Maternal Guidelines: Antenatal, Intrapartum and Postpartum Care ......... 7 Table 3 – NAS Neonatal Guidelines: Newborn Screening and Assessment ..................... 11 Table 4 – NAS Neonatal Guidelines: Newborn Treatment ............................................... 12 Table 5 – NAS Discharge Planning Guidelines .................................................................. 15 Appendix A – NAS Work Group ................................................................................................... 17 Appendix B – Sample Prenatal Specialized Care Plan ................................................................. 18 Appendix C – Algorithm for Assessment and Care of Infants at Risk of NAS ...........................
    [Show full text]
  • Improving Breastfeeding Rates in Neonatal Abstinence Syndrome Infants in the NICU
    Improving breastfeeding rates in Neonatal Abstinence Syndrome infants in the NICU Donna Garey MD MPH Lisa Stellwagen MD UC San Diego Medical Center Division of Neonatology January 2015 FACULTY DISCLOSURE INFORMATION Lisa Stellwagen MD I have a relevant financial relationship to disclose: Medela, Inc: speaker Donna Garey MD MPH I have a relevant financial relationship to disclose: none Objectives • Identify current evidence based reasons to encourage breastfeeding of the Neonatal Abstinence Syndrome (NAS) infant • Identify what concrete steps can be implemented to improve breastfeeding rates at discharge in the NAS infant • Learn the what is currently known about the effects of Marijuana during pregnancy and lactation, and then be able to accurately counsel mothers on this issue Neonatal Abstinence Syndrome (NAS) • Due to abrupt discontinuation of chronic exposure to opioids in utero • Generalized multi-system disorder • Incidence of NAS increasing around the US From: Neonatal Abstinence Syndrome and Associated Health Care Expenditures: United States, 2000-2009 JAMA. 2012;307(18):1934-1940. doi:10.1001/jama.2012.3951 Figure Legend: Error bars indicate 95% CI. P for trend < .001 over the study period. The unweighted sample sizes for mothers diagnosed with and without antepartum opiate use are 987 and 833 494 in 2000; 1058 and 849 133 in 2003; 2160 and 879 910 in 2006; and 4563 and 816 554 in 2009; respectively. Copyright © 2015 American Medical Date of download: 1/27/2015 Association. All rights reserved. From: Neonatal Abstinence Syndrome and Associated Health Care Expenditures: United States, 2000-2009 JAMA. 2012;307(18):1934-1940. doi:10.1001/jama.2012.3951 Figure Legend: NAS indicates neonatal abstinence syndrome.
    [Show full text]
  • ABM Clinical Protocol #21: Guidelines for Breastfeeding and Substance Use Or Substance Use Disorder, Revised 2015
    BREASTFEEDING MEDICINE Volume 10, Number 3, 2015 ABM Protocol ª Mary Ann Liebert, Inc. DOI: 10.1089/bfm.2015.9992 ABM Clinical Protocol #21: Guidelines for Breastfeeding and Substance Use or Substance Use Disorder, Revised 2015 Sarah Reece-Stremtan,1,2 Kathleen A. Marinelli,3,4 and The Academy of Breastfeeding Medicine A central goal of The Academy of Breastfeeding Medicine is the development of clinical protocols for managing common medical problems that may impact breastfeeding success. These protocols serve only as guidelines for the care of breastfeeding mothers and infants and do not delineate an exclusive course of treatment or serve as standards of medical care. Variations in treatment may be appropriate according to the needs of an individual patient. Purpose use of other harmful legal substances, including tobacco and alcohol. Illicit drugs are frequently mixed and extended with he choice of breastfeeding by a pregnant or newly dangerous adulterants that can pose additional threats to the postpartum woman with a history of past or current T health of the mother and the infant. Drug users are at high risk illegal/illicit drug abuse or legal substance use or misuse is for infections such as human immunodeficiency virus and/or challenging for many reasons. The purpose of this protocol is hepatitis B and C. Psychiatric disorders that require phar- to provide literature-based guidelines for the evaluation and macotherapeutic intervention are more prevalent with sub- management of the woman with substance use or a substance stance use, making breastfeeding an even more complicated use disorder who is considering breastfeeding.
    [Show full text]